SCHEMBL2345124

SCHEMBL2345124

Cc1nc(N2CCN(C(=O)OC(C)(C)C)[C@@H](C)C2)ccc1N

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.66
HDAC1 Q13547 6/20 0.57
GPR119 Q8TDV5 2/20 0.46
SUV39H2 Q9H5I1 2/20 0.44
EIF2AK4 Q9P2K8 1/20 0.41
HDAC2 Q92769 2/20 0.40
HDAC3 O15379 1/20 0.40
CYP2C9 P11712 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MAPKAPK3 Q16644 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
SETD7 Q8WTS6 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
DPP4 P27487 1/20 0.39
GRM1 Q13255 3/20 0.39
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2343921 1.00 MAP4K4 (0.66) MAP4K4HDAC1GPR119SUV39H2EIF2AK4
SCHEMBL2343918 1.00 MAP4K4 (0.66) MAP4K4HDAC1GPR119SUV39H2EIF2AK4
SCHEMBL31703517 0.86 MAP4K4 (0.50) MAP4K4HDAC1EIF2AK4DPP4NR1H2
SCHEMBL2338338 0.83 MAP4K4 (0.56) MAP4K4HDAC1GPR119SUV39H2EIF2AK4
SCHEMBL2338334 0.83 MAP4K4 (0.56) MAP4K4HDAC1GPR119SUV39H2EIF2AK4
SCHEMBL2342450 0.83 MAP4K4 (0.56) MAP4K4HDAC1GPR119SUV39H2EIF2AK4
SCHEMBL31327927 0.82 MAP4K4 (0.62) MAP4K4HDAC1GPR119SUV39H2HDAC2
SCHEMBL31104931 0.82 MAP4K4 (0.62) MAP4K4HDAC1GPR119SUV39H2HDAC2
SCHEMBL31105213 0.82 MAP4K4 (0.62) MAP4K4HDAC1GPR119SUV39H2HDAC2
SCHEMBL30426722 0.82 MAP4K4 (0.62) MAP4K4HDAC1GPR119SUV39H2HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150175570-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2015-06-25 US disclosed
US-20150175570-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2015-06-25 US disclosed
US-20150175570-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2015-06-25 US disclosed
US-20140200224-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-17 US disclosed
US-20140200224-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-17 US disclosed
EP-2203426-B9 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2013-02-13 EP disclosed
US-20110319421-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO., KG (DE) 2011-12-29 US disclosed
US-20110319421-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO., KG (DE) 2011-12-29 US disclosed
US-20110319421-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO., KG (DE) 2011-12-29 US disclosed
EP-2203426-B1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2011-08-31 EP disclosed
US-20100210664-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-08-19 US disclosed
US-20100210664-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-08-19 US disclosed
US-20100210664-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-08-19 US disclosed
EP-2203426-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2010-07-07 EP disclosed
WO-2009056600-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175570-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR DRD3, SLC6A3, DRD2 MAP4K4 1530/4885HDAC1 2898/4885GPR119 284/4885
US-20100210664-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR DRD3, SLC6A3, DRD2 MAP4K4 1530/4885HDAC1 2898/4885GPR119 284/4885
US-20140200224-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR DRD3, SLC6A3, DRD2 MAP4K4 1726/4885HDAC1 3464/4885GPR119 235/4885
US-20110319421-A1 BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR DRD3, SLC6A3, DRD2 MAP4K4 1530/4885HDAC1 2898/4885GPR119 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.